Lincoln National Corp Takes Position in Science 37 Holdings, Inc. (NASDAQ:SNCE)

Posted by on May 12th, 2023

Lincoln National Corp bought a new position in shares of Science 37 Holdings, Inc. (NASDAQ:SNCE – Get Rating) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 138,000 shares of the company’s stock, valued at approximately $57,000. Lincoln National Corp owned approximately 0.12% of Science 37 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of SNCE. JPMorgan Chase & Co. lifted its stake in Science 37 by 29.0% during the 1st quarter. JPMorgan Chase & Co. now owns 14,574 shares of the company’s stock worth $78,000 after acquiring an additional 3,272 shares in the last quarter. Citigroup Inc. acquired a new stake in shares of Science 37 in the 1st quarter valued at $37,000. BlackRock Inc. lifted its position in shares of Science 37 by 0.7% during the 1st quarter. BlackRock Inc. now owns 670,846 shares of the company’s stock worth $3,589,000 after purchasing an additional 4,373 shares during the last quarter. Affinity Asset Advisors LLC boosted its position in shares of Science 37 by 47.6% during the 1st quarter. Affinity Asset Advisors LLC now owns 221,382 shares of the company’s stock worth $1,184,000 after acquiring an additional 71,382 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Science 37 by 2.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 260,945 shares of the company’s stock valued at $1,397,000 after purchasing an additional 6,356 shares in the last quarter. Institutional investors and hedge funds own 50.85% of the company’s stock.

Analysts Set New Price Targets

Separately, Robert W. Baird cut their price target on Science 37 from $2.00 to $1.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 7th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Science 37 has an average rating of “Moderate Buy” and a consensus target price of $3.50.

Science 37 Stock Down 5.3 %

NASDAQ:SNCE opened at $0.25 on Friday. The firm’s fifty day simple moving average is $0.30 and its 200-day simple moving average is $0.52. The stock has a market cap of $29.49 million, a PE ratio of -0.54 and a beta of 1.33. Science 37 Holdings, Inc. has a fifty-two week low of $0.19 and a fifty-two week high of $4.31.

Science 37 (NASDAQ:SNCE – Get Rating) last announced its earnings results on Monday, March 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.02. The company had revenue of $15.94 million during the quarter, compared to analysts’ expectations of $14.46 million. Science 37 had a negative net margin of 72.69% and a negative return on equity of 69.42%.

Science 37 Profile

(Get Rating)

Science 37 Holdings, Inc provides technology-based solutions to enable agile clinical trials and decentralized approaches. Its platform enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, and sponsors to power workflows, centralize evidence generation, and harmonize data.

Read More

Institutional Ownership by Quarter for Science 37 (NASDAQ:SNCE)

Receive News & Ratings for Science 37 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Science 37 and related companies with MarketBeat.com's FREE daily email newsletter.